Sarepta Stock Underperform Rating Reiterated by BofA: What Indian Investors Need to Know
Bank of America (BofA) has reiterated its Underperform rating on Sarepta Therapeutics stock, citing regulatory risks. What does this mean for Indian investors and how can they navigate the complex landscape of international stocks?